SUMMARY A study was performed to assess whether plasma and myocardial concentrations of amiodarone correlated with changes on the surface electrocardiogram. Nine patients-seven with angina and two with paroxysmal ventricular tachycardia-were treated with oral amiodarone (200-400 mg daily) for at least nine months before undergoing cardiac surgery. QT intervals were measured from lead II of the surface electrocardiograms recorded before amiodarone treatment and immediately before surgery. Patients with prominent U waves after taking amiodarone were excluded from the study. Plasma and myocardial samples were collected at the beginning of the surgical procedure for estimating plasma and myocardial concentrations using the high performance liquid chromatographic technique. Amiodarone caused a significant lengthening of the QTc interval. There was a good correlation between plasma and myocardial concentrations, and both correlated well with the percentage increase in the QTc interval. Although there was a strong correlation between the dosage given (mg/kg/day) and both plasma and myocardial concentrations, the correlation with the percentage increase in the QTc interval was weaker but still highly significant. Despite previous reports to the contrary, the findings indicate that the plasma concentration of amiodarone does correlate well with the myocardial concentration. 
Amiodarone was first introduced as an antianginal drug.1 2 Its electrophysiological effect of prolonging the action potential was discovered later,34 and amiodarone is now recognised as a Vaughan Williams class III antiarrhythmic agent. 5 The drug is widely used for the treatment of both angina and arrhythmias. 6 The pharmacokinetics of amiodarone received scant attention, however, until the introduction of a high performance liquid chromatographic technique allowed the fast and accurate assay of the drug in plasma.78 Amiodarone is highly tissue bound,9 and it was thought that blood concentrations of the drug were of only limited clinical use'0 and did not correlate with its efficacy. Recently, this widely held belief has been challenged by reports of a correlation between plasma concentrations and efficacy.'" It has also been reported that A large series of 30 patients has been studied to determine the relation between myocardial and plasma concentrations of amiodarone.12 Of these 30 patients, nine met all the specific criteria for the present study: (a) no treatment with other drugs known to affect the QT interval; (b) no bundle branch block, pre-excitation, or other form of abnormal QRS complex; (c) no prominent U waves on the electrocardiogram before treatment with amiodarone; and (d) availability of good quality preoperative and postoperative electrocardiograms. All routine haematological and biochemical investigations were normal. Written informed consent was obtained from each patient before entry to the study.
ELECTROCARDIOGRAMS
Twelve lead electrocardiograms were recorded before the start of amiodarone treatment and again just before surgery. The QT intervals were measured directly from standard lead II using a digitising system on line to a computer. The sensitivity of the measuring system (at a recording speed of 25 mm/s) was 2 ms. The measurements were made double blind (as far as the electrocardiographic changes induced by amiodarone on the electrocardiogram would allow) by two different operators. Interobserver error was small, and the mean of both values was used for calculating the QTc interval. The QT interval was measured from the beginning of the QRS complex to the end of the T wave, including the reduplication of the T wave that often appears with long term amiodarone treatment (Fig. 1 ). The measured QT intervals were corrected according to heart rate using Bazett's hyperbolic formula. Where a correlation between two variables was sought, least squares linear regression analysis was used, and the probability (p) deduced from the regression coefficient (r). Data were compared using Student's t test for paired data. Results were considered to be statistically significant when p<0-05.
Results
The mean QTc interval before amiodarone treatment was 454± 34 ms and during amiodarone treatment 533±61 ms. The increase of 79 ms was significant at the 1% level.
The percentage increase in the QTc interval ranged from 6.8% to 35*8% with a mean increase of 18*5%.
The linear regression between the oral dose (mg/kg! day) and the percentage increase in the QTc interval showed that the higher the dosage the greater the increase in QTc. The correlation coefficient (r) was 0.88, and the intercept 0*96 mg/kg/day (Fig. 2) .
Plasma concentrations ranged from 0-13 mg/l to 0*76 mg/l (mean 037 mg/l) and myocardial concentrations from 3-46 mg/kg to 11*16 mg/kg (mean coefficients r=094 for plasma and r=093 for myocardium) were obtained. For the plasma concentrations the intercept was 1*71 mg/kg/day and for the myocardial concentrations the intercept was 0-27 mg/kg/day (Fig. 3) . There was a strong correlation between plasma and myocardial concentrations with an r value of 0*92 and an intercept of -0-27 mg/l (Fig. 4) .
Linear regression showed a good correlation between percentage increase in the QTc interval and plasma concentration of amiodarone with an r value of 0O92 and an intercept of -013 mg/l. Similarly, the correlation between myocardial concentration of the drug and percentage increase in the QTc interval was extremely good with an r value of 0-96 and an intercept of 1*40 mg/kg (Fig. 5) .
These results are summarised in the Table. Myocardial concentration (mg/kg) 
Discussion
The antiarrhythmic efficacy of amiodarone is now well proved, and it is widely used for a variety of atrial, junctional, and ventricular arrhythmias. 4 Amiodarone treatment is, however, difficult to monitor because of the tissue, and particularly myocardial, affinity for the drug. The Amiodarone and the QT interal drug both correlated well with the dose given and with each other. The relation between plasma concentration and dosage (Fig. 3) suggests that there is a dose threshold that must be exceeded before the drug appears in the plasma. This has also been shown in a larger study of 30 patients.12 This phenomenon suggests that the drug is avidly taken up by tissuesincluding the myocardium-with plasma concentrations not measurable until the tissues have removed a considerable amount of the drug from the circulation. This is in part confirmed by the relation between myocardial concentrations and drug dosage in which-in contrast to plasma-no threshold phenomenon is seen. Nevertheless, the myocardial drug concentration can be inferred from concentrations of drug in the plasma. Thus in contradiction of widely accepted dogmas, this study shows that long term amiodarone treatment can be monitored using trough plasma concentration estimates. This new conclusion probably relates to the improved accuracy of the present method (8.3 ng of amiodarone), because concentrations in plasma are 10 times lower than those in the myocardium.
In this group of patients, atrial myocardial biopsy specimens were examined to determine the relation between an increase in the QT interval and the myocardial amiodarone concentration. A previous studyl2 had already shown that there is no statistical difference between amiodarone concentrations in atrial and venticular myocardium. Even 
